Pozelimab

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent business highlights. “Our results during the second quarter highlight Alnylam’s unique ability to quickly deliver and enable commercial access to innovative medicines for patients, while continuing to advance our high-value pipeline of investigational RNAi therapeutics,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. “Our first full quarter of AMVUTTRA sales in ATTR-CM provided a significant inflection in our TTR franchise revenues, with total net product revenues growing 64% year-over-year. While still early in the launch, we are very encouraged by the initial pace of uptake, evidence of the clear need for a novel mechanism in ATTR-CM and the effectiveness of our broad patient access efforts. Based on the strong progress during the first half of 2025 and our confidence in the overall business for the rest of the year, we are raising our total net product revenue guidance range by 27% at the midpoint, driven by an upward revision to our TTR franchise revenue guidance. Dr. Greenstreet continued, “We also continue to advance key programs in our robust pipeline, with the TRITON-CM Phase 3 trial of nucresiran in ATTR-CM underway, and two more Phase 3 trials on track to start this year: TRITON-PN for nucresiran in hATTR-PN and the cardiovascular outcomes trial of zilebesiran in hypertension. The remarkable pace and depth of our progress positions us to deliver on our Alnylam P5x25 goals as we advance toward sustainable profitability and solidify ourselves as a top-tier biotech company delivering transformational innovation to patients.” Second Quarter 2025 and Recent Significant Business Highlights Total TTR: AMVUTTRA® (vutrisiran) & ONPATTRO® (patisiran) Achieved global net product revenues for AMVUTTRA and ONPATTRO for the second quarter of $492 million and $53 million, respectively, representing $544 million in total TTR net product revenues and 77% total TTR growth compared to Q2 2024. Achieved approximately 1,400 ATTR-CM patients on AMVUTTRA as of June 30, 2025. Strong progress achieving approvals of AMVUTTRA for ATTR-CM in numerous global markets. Received regulatory approvals from the Brazilian Health Regulatory Agency (ANVISA), European Commission (EC), UK Medicines and Healthcare Products Regulatory Agency (MHRA), and Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Received regulatory approvals from the Brazilian Health Regulatory Agency (ANVISA), European Commission (EC), UK Medicines and Healthcare Products Regulatory Agency (MHRA), and Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Presented additional 42-month data from the HELIOS-B Phase 3 trial of vutrisiran as a late-breaking abstract at the Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology. The results reinforce the primary HELIOS-B analysis showing vutrisiran’s effect on all-cause mortality (ACM) and further demonstrate that vutrisiran reduced CV mortality. Through 42 months, vutrisiran reduced the risk of ACM by 36% (95% CI: 0.46, 0.88; p = 0.007) and the risk of CV mortality by 33% (95% CI: 0.47, 0.96; p = 0.038) in the overall population, compared to placebo. These data were also published in the Journal of the American College of Cardiology . The results reinforce the primary HELIOS-B analysis showing vutrisiran’s effect on all-cause mortality (ACM) and further demonstrate that vutrisiran reduced CV mortality. Through 42 months, vutrisiran reduced the risk of ACM by 36% (95% CI: 0.46, 0.88; p = 0.007) and the risk of CV mortality by 33% (95% CI: 0.47, 0.96; p = 0.038) in the overall population, compared to placebo. These data were also published in the Journal of the American College of Cardiology . Initiated the TRITON-CM Phase 3 trial of nucresiran in patients with ATTR-CM. TRITON-CM is an event-driven cardiovascular outcomes trial expected to enroll 1,200 patients with wild-type TTR or any TTR variant and confirmed cardiomyopathy, including patients on background stabilizer therapy. The primary endpoint is a composite of all-cause mortality and cardiovascular events. Alnylam announces today that nucresiran has received Fast Track Designation from the FDA's Division of Cardiology and Nephrology for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis in adults to reduce mortality, cardiovascular hospitalizations, and urgent heart failure visits. Alnylam announces today that nucresiran has received Fast Track Designation from the FDA's Division of Cardiology and Nephrology for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis in adults to reduce mortality, cardiovascular hospitalizations, and urgent heart failure visits. Total Rare: GIVLAARI® (givosiran) & OXLUMO® (lumasiran) Achieved global net product revenues for GIVLAARI and OXLUMO for the second quarter of $81 million and $47 million, respectively, representing $128 million in total Rare net product revenue and 24% total Rare growth compared to Q2 2024. Other Highlights Presented Phase 1 multiple and single dose data for mivelsiran in Alzheimer’s disease in an oral presentation at the Alzheimer’s Association International Conference (AAIC). Single and multiple doses of mivelsiran were generally well tolerated and continued to demonstrate robust, durable, dose-dependent reductions of soluble amyloid precursor protein beta (sAPPβ) in the cerebrospinal fluid (CSF). Further lowering of sAPPβ in CSF was observed after a second 50 mg dose of mivelsiran. These results support further evaluation of mivelsiran in Alzheimer's disease and cerebral amyloid angiopathy. Single and multiple doses of mivelsiran were generally well tolerated and continued to demonstrate robust, durable, dose-dependent reductions of soluble amyloid precursor protein beta (sAPPβ) in the cerebrospinal fluid (CSF). Further lowering of sAPPβ in CSF was observed after a second 50 mg dose of mivelsiran. These results support further evaluation of mivelsiran in Alzheimer's disease and cerebral amyloid angiopathy. Initiated a Phase 1 clinical trial for ALN-4324 , an insulin sensitizer that targets GRB14, for the treatment of type 2 diabetes. Alnylam’s partner, Agios Pharmaceuticals, has received Investigational New Drug (IND) clearance for AG-236 (ALN-TMP) , an RNAi therapeutic targeting TMPRSS6 intended for the treatment of polycythemia vera (PV), and initiated the Phase 1 healthy volunteer study. Additional Business Updates Published 2024 Corporate Responsibility Report . Key Upcoming Events Alnylam announces today that it will present results from the KARDIA-3 Phase 2 trial of zilebesiran in patients with hypertension during a Hot Line Session at the European Society of Cardiology (ESC) Congress in Madrid, Spain on August 30, 2025. In addition, in the second half of 2025, Alnylam expects to: Initiate a Phase 3 cardiovascular outcomes trial of zilebesiran , in collaboration with its partner Roche Initiate the TRITON-PN Phase 3 trial of nucresiran in hATTR-PN Initiate a Phase 2 trial of mivelsiran in Alzheimer’s disease In addition, Alnylam's partner, Regeneron Pharmaceuticals, plans to share results from the Phase 3 trial of cemdisiran tested as a monotherapy and in combination with pozelimab in patients with myasthenia gravis in the second half of 2025. Financial Results for the Quarter Ended June 30, 2025 Three Months Ended June 30, % Change (In thousands, except per share amounts and percentages) 2025 2024 Total revenues $ 773,689 $ 659,825 17 % GAAP (Loss) income from operations $ (16,199 ) $ 48,614 (133 )% Non-GAAP Income from operations $ 95,481 $ 137,902 (31 )% GAAP Net loss per common share — basic and diluted $ (0.51 ) $ (0.13 ) 292 % Non-GAAP Net income per common share — basic $ 0.34 $ 0.58 (41 )% Non-GAAP Net income per common share — diluted $ 0.32 $ 0.56 (43 )% For an explanation of our use of non-GAAP financial measures, refer to the “Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measure, see the tables at the end of this press release. Revenue Summary Three Months Ended June 30, % Change % Change at CER** (In thousands, except percentages) 2025 2024 Net product revenues: AMVUTTRA $ 491,953 $ 230,109 114 % 112 % ONPATTRO 52,538 77,244 (32 )% (33 )% Total TTR net product revenues 544,491 307,353 77 % 75 % GIVLAARI 80,849 62,127 30 % 29 % OXLUMO 46,872 40,608 15 % 13 % Total Rare net product revenues 127,721 102,735 24 % 23 % Total net product revenues 672,212 410,088 64 % 62 % Net revenues from collaborations: Roche 18,267 16,506 11 % 11 % Regeneron Pharmaceuticals 32,542 207,429 (84 )% (84 )% Novartis AG — 2,304 (100 )% (100 )% Other 10,687 1,099 * * Total net revenues from collaborations 61,496 227,338 (73 )% (73 )% Royalty revenue 39,981 22,399 78 % 78 % Total revenues $ 773,689 $ 659,825 17 % 16 % * Indicates the percentage change period over period is greater than 500% ** Change at constant exchange rates, or CER, represents growth calculated as if exchange rates had remained unchanged from those used during the three months ended June 30, 2024. CER is a non-GAAP financial measure. Total Net Product Revenues Total net product revenues increased 64% and 62% at actual currency and CER, respectively, during the three months ended June 30, 2025, as compared to the same period in 2024, primarily due to growth from AMVUTTRA driven by increased patient demand, mainly in patients with ATTR-CM in the U.S., which was partially offset by a decrease in ONPATTRO due to patient switches to AMVUTTRA, and due to growth from an increased number of patients on GIVLAARI and OXLUMO. Net Revenues from Collaborations Net revenues from collaborations decreased during the three months ended June 30, 2025, as compared to the same period in 2024, primarily driven by recognition of $185.0 million of revenue under our collaboration with Regeneron Pharmaceuticals in the three months ended June 30, 2024, as we modified the collaboration in June 2024 and provided Regeneron with an exclusive license to develop, manufacture and commercialize cemdisiran as a monotherapy. Operating Expense Summary Three Months Ended June 30, % Change (In thousands, except percentages) 2025 2024 Cost of goods sold $ 142,029 $ 67,271 111 % % of net product revenues 21.1 % 16.4 % Cost of collaborations and royalties 924 1,401 (34 )% GAAP Research and development expenses 323,621 294,142 10 % Non-GAAP Research and development expenses 274,069 246,027 11 % GAAP Selling, general and administrative expenses 323,314 248,397 30 % Non-GAAP Selling, general and administrative expenses $ 261,186 $ 207,224 26 % Cost of Goods Sold Cost of goods sold, including cost of goods sold as a percentage of net product revenues, increased during the three months ended June 30, 2025, as compared to the same period in 2024, primarily as a result of increased sales of AMVUTTRA and an associated increase in royalties payable on net sales of AMVUTTRA. Research & Development (R&D) Expenses GAAP and non-GAAP R&D expenses for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to increased clinical trial expenses associated with startup activities for zilebesiran in the Phase 3 cardiovascular outcomes trial and nucresiran in the TRITON-CM Phase 3 trial in patients with ATTR-CM. Selling, General & Administrative (SG&A) Expenses GAAP and non-GAAP SG&A expenses for the three months ended June 30, 2025 increased as compared to the same period in 2024, primarily due to higher employee compensation costs and increased marketing investment associated with AMVUTTRA launch in ATTR-CM. Additionally, GAAP SG&A expenses increased due to higher stock-based compensation expenses. Other Financial Highlights Interest expense Interest expense for the three months ended June 30, 2025 of $40.2 million included interest of $36.5 million attributed to the liability related to the sale of future Leqvio royalties. Total other expense, net Total other expense, net for the three months ended June 30, 2025 of $19.2 million included a charge associated with the change in fair value of the development derivative liability of $15.3 million primarily driven by updates to estimated royalties due to Blackstone on net sales of AMVUTTRA. Provision for income taxes During the three months ended June 30, 2025, we recorded a provision for income taxes of $30.9 million primarily due to income generated in Switzerland, as well as state income taxes in the U.S. We will utilize deferred tax assets in Switzerland to offset current cash tax liabilities and will continue to maintain a full valuation allowance against our net deferred tax assets in the U.S. and certain deferred tax assets in Switzerland. Financial position Cash, cash equivalents and marketable securities were $2.86 billion as of June 30, 2025, as compared to $2.63 billion as of March 31, 2025, with the increase primarily driven by net cash inflows from operating activities and proceeds from exercise of employee stock options. Net cash provided by operating activities for the three months ended June 30, 2025 included $14.4 million of payments associated with the liability related to the sale of future Leqvio royalties recorded to interest expense. Net cash provided by financing activities for the three months ended June 30, 2025 included $27.5 million of payments to Blackstone associated with achieved development and regulatory approval milestones for the development derivative liability, as well as royalties on net sales of AMVUTTRA. A reconciliation of our GAAP to non-GAAP financial results is included in the tables at the end of this press release. 2025 Financial Guidance Full-year 2025 financial guidance is updated and consists of the following: Item Prior FY 2025 Guidance Updated FY 2025 Guidance Total TTR net product revenues (PN & CM) (AMVUTTRA, ONPATTRO)1 $1,600 million - $1,725 million $2,175 million - $2,275 million Total Rare net product revenues (GIVLAARI, OXLUMO) $450 million - $525 million $475 million - $525 million Total net product revenues $2,050 million - $2,250 million $2,650 million - $2,800 million Net product revenues growth vs. 2024 at currency exchange rates as of June 30, 20251 25% to 37% 61% to 70% Net product revenues growth vs. 2024 at constant exchange rates2 26% to 39% 59% to 68% Net revenues from collaborations and royalties $650 million - $750 million Reiterate FY guidance GAAP R&D and SG&A expenses $2,370 million - $2,530 million $2,445 million - $2,575 million Non-GAAP R&D and SG&A expenses3 $2,100 million - $2,200 million Reiterate FY guidance Non-GAAP Operating income3 Achieve profitability Reiterate FY guidance 1 Full-year 2025 guidance utilizing currency exchange rates as of June 30, 2025: 1 EUR = 1.17 USD and 1 USD = 144 JPY 2 Representing growth calculated as if the exchange rates had remained unchanged from those used in 2024, which is a non-GAAP financial measure 3 Excludes $270 million - $330 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses in the prior FY 2025 guidance and $345 million - $375 million of stock-based compensation expense in the updated FY 2025 guidance Use of Non-GAAP Financial Measures This press release contains non-GAAP financial measures, including expenses adjusted to exclude certain non-cash expenses and non-recurring gains or losses outside the ordinary course of the Company’s business. These measures are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are stock-based compensation expenses and realized and unrealized gains or losses on marketable equity securities. The Company has excluded the impact of stock-based compensation expense, which may fluctuate from period to period based on factors including the variability associated with performance-based grants for stock options and restricted stock units and changes in the Company’s stock price, which impacts the fair value of these awards. The Company has excluded the impact of the realized and unrealized gains or losses on marketable equity securities because the Company does not believe these adjustments accurately reflect the performance of the Company’s ongoing operations for the period in which such gains or losses are reported, as their sole purpose is to adjust amounts on the balance sheet. Percentage changes in revenue growth at CER are presented excluding the impact of changes in foreign currency exchange rates for investors to understand the underlying business performance. The current period’s foreign currency revenue values are converted into U.S. dollars using the average exchange rates from the prior period. The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance and are better able to compare the Company’s performance between periods. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between GAAP and non-GAAP measures is provided later in this press release. Conference Call Information Management will provide an update on the Company and discuss second quarter 2025 results as well as expectations for the future via conference call on Thursday, July 31, 2025 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About AMVUTTRA® (vutrisiran) AMVUTTRA® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection by a healthcare professional, AMVUTTRA is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults and is approved in the U.S., Brazil, the European Union, the United Kingdom, and Japan for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. For more information about AMVUTTRA, including the full U.S. Prescribing Information, visit AMVUTTRA.com. About ONPATTRO® (patisiran) ONPATTRO is an RNAi therapeutic that is approved in the United States and Canada for the treatment of adults with hATTR amyloidosis with polyneuropathy. ONPATTRO is also approved in the European Union, Switzerland and Brazil for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy, and in Japan for the treatment of hATTR amyloidosis with polyneuropathy. ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is designed to target and silence TTR messenger RNA, thereby reducing the production of TTR protein before it is made. Reducing the pathogenic protein leads to a reduction in amyloid deposits in tissues. For more information about ONPATTRO, including full Prescribing Information, visit ONPATTRO.com. About GIVLAARI® (givosiran) GIVLAARI (givosiran) is an RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) approved in the United States and Brazil for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is also approved in the European Union for the treatment of AHP in adults and adolescents aged 12 years and older. In the pivotal trial, GIVLAARI was shown to significantly reduce the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or intravenous hemin administration at home compared to placebo. GIVLAARI is Alnylam’s first commercially available therapeutic based on its Enhanced Stabilization Chemistry ESC-GalNAc conjugate technology to increase potency and durability. GIVLAARI is administered via subcutaneous injection once monthly at a dose based on actual body weight and should be administered by a healthcare professional. GIVLAARI works by specifically reducing elevated levels of ALAS1 messenger RNA (mRNA), leading to reduction of toxins associated with attacks and other disease manifestations of AHP. For more information about GIVLAARI, including the full U.S. Prescribing Information, visit GIVLAARI.com. About OXLUMO® (lumasiran) OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1). HAO1 encodes glycolate oxidase (GO). Thus, by silencing HAO1 and depleting the GO enzyme, OXLUMO inhibits production of oxalate – the metabolite that directly contributes to the pathophysiology of PH1. OXLUMO utilizes Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. OXLUMO has received regulatory approvals from the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients and from the European Medicines Agency (EMA) for the treatment of PH1 in all age groups. In the pivotal ILLUMINATE-A trial, OXLUMO was shown to significantly reduce levels of urinary oxalate relative to placebo, with the majority of patients reaching normal or near-normal levels. In the ILLUMINATE-B pediatric Phase 3 trial, OXLUMO demonstrated an efficacy and safety profile consistent to that observed in ILLUMINATE-A. In the ILLUMINATE-C trial, OXLUMO resulted in substantial reductions in plasma oxalate in patients with advanced PH1. Across all three studies, injection site reactions (ISRs) were the most common drug-related adverse reaction. OXLUMO is administered via subcutaneous injection once monthly for three months, then once quarterly beginning one month after the last loading dose at a dose based on actual body weight. For patients who weigh less than 10 kg, ongoing dosing remains monthly. OXLUMO should be administered by a healthcare professional. For more information about OXLUMO, including the full U.S. Prescribing Information, visit OXLUMO.com. About LNP Technology Alnylam has licenses to Arbutus Biopharma lipid nanoparticle (LNP) intellectual property for use in RNAi therapeutic products using LNP technology. About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), which are being developed and commercialized by Alnylam, and Leqvio® (inclisiran) and Qfitlia™ (fitusiran), which are being developed and commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram. Alnylam Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding Alnylam’s ability to quickly deliver and enable commercial access to medicines for patients and to continue to advance its pipeline of RNAi therapeutics; the success of Alnylam’s commercial launch of AMVUTTRA for ATTR-CM in the U.S. and other territories, including the demand for AMVUTTRA and the effectiveness of Alnylam’s patient access efforts; the timing of commencement of Alnylam’s clinical trials, including TRITON-PN, the cardiovascular outcomes trial of zilebesiran, and a Phase 2 study of mivelsiran in Alzheimer’s disease; Alnylam’s ability to deliver on its Alnylam P5x25 goals and to achieve sustainable profitability and become a top-tier biotech company delivering transformational innovation to patients; and Alnylam’s projected commercial and financial performance, including the updated expected range, for 2025, of TTR net product revenues, Rare net product revenues, total net product revenues, and net revenues from collaborations and royalties, and the expected range of aggregate annual GAAP and non-GAAP R&D and SG&A expenses and non-GAAP operating income for 2025, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam’s ability to successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates, including zilebesiran, nucresiran and mivelsiran; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, including vutrisiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam’s approved products globally; delays, interruptions or failures in the manufacture and supply of Alnylam’s product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, and Regeneron; the outcome of litigation; the risk of future government investigations; and unexpected expenditures; as well as those risks and uncertainties more fully discussed in the “Risk Factors” filed with Alnylam’s 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements. This release discusses investigational RNAi therapeutics and uses of previously approved RNAi therapeutics in development and is not intended to convey conclusions about efficacy or safety as to those investigational therapeutics or uses. There is no guarantee that any investigational therapeutics or expanded uses of commercial products will successfully complete clinical development or gain health authority approval. ALNYLAM PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share amounts) June 30, 2025 December 31, 2024 ASSETS (Unaudited) Current assets: Cash and cash equivalents $ 1,113,685 $ 966,428 Marketable debt securities 1,743,900 1,719,920 Marketable equity securities — 8,156 Accounts receivable, net 567,112 405,308 Inventory 71,688 78,509 Prepaid expenses and other current assets 147,314 116,964 Total current assets 3,643,699 3,295,285 Property, plant and equipment, net 499,791 502,784 Operating lease right-of-use assets 192,401 191,148 Deferred tax assets 104,363 116,863 Restricted investments 68,593 68,593 Other assets 57,172 65,310 Total assets $ 4,566,019 $ 4,239,983 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 102,393 $ 88,415 Accrued expenses 918,966 793,692 Operating lease liabilities 46,097 41,886 Deferred revenue 15,080 55,481 Liability related to the sale of future royalties 97,523 113,018 Development derivative liability 120,788 93,780 Total current liabilities 1,300,847 1,186,272 Operating lease liabilities, net of current portion 224,445 229,541 Convertible debt 1,026,522 1,024,621 Liability related to the sale of future royalties, net of current portion 1,345,147 1,334,353 Development derivative liability, net of current portion 407,535 393,139 Other liabilities 10,932 4,969 Total liabilities 4,315,428 4,172,895 Stockholders' equity: Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2025 and December 31, 2024 — — Common stock, $0.01 par value per share, 250,000 shares authorized; 130,977 shares issued and outstanding as of June 30, 2025; 129,294 shares issued and outstanding as of December 31, 2024 1,310 1,293 Additional paid-in capital 7,690,737 7,388,061 Accumulated other comprehensive loss (29,952 ) (34,518 ) Accumulated deficit (7,411,504 ) (7,287,748 ) Total stockholders' equity 250,591 67,088 Total liabilities and stockholders' equity $ 4,566,019 $ 4,239,983 ALNYLAM PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) Three Months Ended Six Months Ended June 30, 2025 June 30, 2024 June 30, 2025 June 30, 2024 Statements of Operations Revenues: Net product revenues $ 672,212 $ 410,088 $ 1,140,750 $ 775,251 Net revenues from collaborations 61,496 227,338 160,681 345,886 Royalty revenue 39,981 22,399 66,447 33,021 Total revenues 773,689 659,825 1,367,878 1,154,158 Operating costs and expenses: Cost of goods sold 142,029 67,271 212,212 121,884 Cost of collaborations and royalties 924 1,401 1,782 12,764 Research and development 323,621 294,142 588,743 555,137 Selling, general and administrative 323,314 248,397 563,263 459,194 Total operating costs and expenses 789,888 611,211 1,366,000 1,148,979 (Loss) income from operations (16,199 ) 48,614 1,878 5,179 Other (expense) income: Interest expense (40,246 ) (33,258 ) (78,892 ) (68,511 ) Interest income 27,486 29,182 56,159 58,827 Other expense, net (6,399 ) (55,705 ) (56,099 ) (70,249 ) Total other expense, net (19,159 ) (59,781 ) (78,832 ) (79,933 ) Loss before income taxes (35,358 ) (11,167 ) (76,954 ) (74,754 ) Provision for income taxes (30,919 ) (5,722 ) (46,802 ) (8,070 ) Net loss $ (66,277 ) $ (16,889 ) $ (123,756 ) $ (82,824 ) Net loss per common share — basic and diluted $ (0.51 ) $ (0.13 ) $ (0.95 ) $ (0.66 ) Weighted-average common shares used to compute basic and diluted net loss per common share 130,628 126,733 130,155 126,435 ALNYLAM PHARMACEUTICALS, INC. RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES (In thousands, except per share amounts) (Unaudited) Three Months Ended June 30, 2025 June 30, 2024 Reconciliation of GAAP to Non-GAAP Research and development expenses: GAAP Research and development expenses $ 323,621 $ 294,142 Less: Stock-based compensation expenses (49,552 ) (48,115 ) Non-GAAP Research and development expenses $ 274,069 $ 246,027 Reconciliation of GAAP to Non-GAAP Selling, general and administrative expenses: GAAP Selling, general and administrative expenses $ 323,314 $ 248,397 Less: Stock-based compensation expenses (62,128 ) (41,173 ) Non-GAAP Selling, general and administrative expenses $ 261,186 $ 207,224 Reconciliation of GAAP to Non-GAAP Income (loss) from operations: GAAP (Loss) income from operations $ (16,199 ) $ 48,614 Add: Stock-based compensation expenses 111,680 89,288 Non-GAAP Operating income $ 95,481 $ 137,902 Reconciliation of GAAP to Non-GAAP Net income (loss): GAAP Net loss $ (66,277 ) $ (16,889 ) Add: Stock-based compensation expenses 111,680 89,288 Add: Realized and unrealized loss on marketable equity securities 1,350 1,367 Less: Income tax effect of GAAP to non-GAAP reconciling items (2,631 ) — Non-GAAP Net income $ 44,122 $ 73,766 Reconciliation of GAAP to Non-GAAP Net income (loss) per common share - basic: GAAP Net loss per common share — basic $ (0.51 ) $ (0.13 ) Add: Stock-based compensation expenses 0.85 0.70 Add: Realized and unrealized loss on marketable equity securities 0.01 0.01 Less: Income tax effect of GAAP to non-GAAP reconciling items (0.02 ) — Non-GAAP Net income per common share — basic $ 0.34 $ 0.58 Reconciliation of GAAP to Non-GAAP Net income (loss) per common share - diluted: GAAP Net loss per common share - diluted $ (0.51 ) $ (0.13 ) Add: Stock-based compensation expenses 0.85 0.70 Add: Realized and unrealized loss on marketable equity securities 0.01 0.01 Less: Income tax effect of GAAP to non-GAAP reconciling items (0.02 ) — Less: Impact to earnings per common share as a result of dilutive weighted-average common shares outstanding during the period* (0.02 ) (0.02 ) Non-GAAP Net income per common share - diluted* $ 0.32 $ 0.56 *Non-GAAP Net income per common share - diluted is calculated by dividing the non-GAAP net income by the weighted-average number of common shares and dilutive potential common share equivalents outstanding during the period. The dilutive weighted-average common shares outstanding for the three months ended June 30, 2025 would be 137,089 thousand shares. Please note that the figures presented above may not sum exactly due to rounding ALNYLAM PHARMACEUTICALS, INC. RECONCILIATION OF GAAP TO NON-GAAP PRODUCT REVENUE GROWTH AT CONSTANT CURRENCY (Unaudited) June 30, 2025 Three Months Ended AMVUTTRA net product revenue growth, as reported 114 % Add: Impact of foreign currency translation (2 ) AMVUTTRA net product revenue growth at constant currency 112 % ONPATTRO net product revenue growth, as reported (32 )% Add: Impact of foreign currency translation (1 ) ONPATTRO net product revenue growth at constant currency (33 )% Total TTR net product revenue growth, as reported 77 % Add: Impact of foreign currency translation (2 ) Total TTR net product revenue growth at constant currency 75 % GIVLAARI net product revenue growth, as reported 30 % Add: Impact of foreign currency translation (1 ) GIVLAARI net product revenue growth at constant currency 29 % OXLUMO net product revenue growth, as reported 15 % Add: Impact of foreign currency translation (2 ) OXLUMO net product revenue growth at constant currency 13 % Total Rare net product revenue growth, as reported 24 % Add: Impact of foreign currency translation (1 ) Total Rare net product revenue growth at constant currency 23 % Total net product revenue growth, as reported 64 % Add: Impact of foreign currency translation (2 ) Total net product revenue growth at constant currency 62 % Total revenue growth, as reported 17 % Add: Impact of foreign currency translation (1 ) Total revenue growth at constant currency 16 %

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer Approval based on pivotal Phase 1/2 LINKER-MM1 trial; results reported were among the highest overall (70%) and complete response rates (45%) for bispecific antibodies in heavily pre-treated multiple myeloma patients Lynozyfic provides a patient-centric response-adapted dosing regimen TARRYTOWN, NY, USA I July 02, 2025 I Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody. Lynozyfic was granted accelerated approval based on response rate and durability of response in the LINKER-MM1 trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Lynozyfic is the first FDA-approved BCMAxCD3 bispecific antibody that can be dosed every two weeks starting at week 14, and every four weeks if a very good partial response (VGPR) or better is achieved following completion of at least 24 weeks of therapy. The regimen includes hospitalization for safety during the step-up dosing period (one 24-hour period after the first step-up dose, and another 24-hour period after the second step-up dose). “The FDA approval of Lynozyfic represents meaningful progress for the multiple myeloma community. Lynozyfic demonstrated early, deep and durable responses in heavily pre-treated patients, which I saw firsthand in clinical trials,” said Sundar Jagannath, M.D., Network Director of the Center of Excellence for Multiple Myeloma at Mount Sinai in New York City and a trial investigator. “Lynozyfic has a convenient response-adapted dosing regimen, which provides the potential to extend time between doses. This is a significant patient-centric advancement that could help reduce treatment burden.” The FDA approval is based on results from the pivotal Phase 1/2 LINKER-MM1 trial investigating linvoseltamab in R/R MM in which patients (n=80) experienced a: The prescribing information for Lynozyfic has a Boxed Warning for cytokine release syndrome (CRS) and neurologic toxicity – including immune effector cell-associated neurotoxicity syndrome – in addition to warnings and precautions for infections, neutropenia, hepatotoxicity and embryo-fetal toxicity. The most common adverse reactions (≥20%) in the safety population of LINKER-MM1 (n=117) were musculoskeletal pain, CRS, cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache and dyspnea. The most common Grade 3 or 4 laboratory abnormalities (≥30%) were decreased lymphocyte count, decreased neutrophil count, decreased hemoglobin and decreased white blood cell count. Lynozyfic is available only through a restricted program called the Lynozyfic Risk Evaluation and Mitigation Strategy (REMS). Details of the Important Safety Information are included below. “The FDA approval of Lynozyfic reinforces the strength of our bispecific antibody program as well as our commitment to delivering critical medicines to the cancer community,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron. “With a 70% overall response rate in heavily pre-treated patients, we believe Lynozyfic is poised to potentially become a new standard of care for multiple myeloma. Furthermore, given the strength of the data, we are rapidly advancing our broad clinical development program for Lynozyfic – exploring its use in earlier lines of therapy as monotherapy and in novel combinations – as we aim to meaningfully advance care for patients.” Regeneron is committed to helping patients who have been prescribed Lynozyfic access their medication. The company has launched Lynozyfic Surround™, which offers financial and educational resources to help support patients throughout their treatment journey. For more information, patients can call 1-844-RGN-HEME (1-844-746-4363). “Even though the number of treatment options for multiple myeloma has expanded in recent years, it remains an incurable disease with considerable unmet need, especially among patients who have undergone multiple lines of treatment,” said Diane Moran, R.N., M.A., Ed.M., Chief Executive Officer (Interim) and Senior Vice President of Strategic Planning at the International Myeloma Foundation. “The FDA approval of Lynozyfic is a welcome milestone. It provides appropriate multiple myeloma patients and their care teams with a novel patient-centric treatment option that includes a dosing schedule that can be adapted based on patient response. We appreciate Regeneron’s continued research to further advance treatment for this community.” About Multiple Myeloma As the second most common blood cancer, there are over 187,000 new cases of MM diagnosed globally every year, with more than 36,000 diagnosed and 12,000 deaths anticipated in the U.S. in 2025. In the U.S., there are approximately 8,000 people who have MM that has progressed after three lines of therapy, and 4,000 whose disease has progressed after four or more therapies. The disease is characterized by the proliferation of cancerous plasma cells (MM cells) that crowd out healthy blood cells in the bone marrow, infiltrate other tissues and cause potentially life-threatening organ injury. Despite treatment advances, MM is not curable and while current treatments are able to slow progression of the cancer, most patients will ultimately experience cancer progression and require additional therapies. About Lynozyfic™ (linvoseltamab-gcpt) Lynozyfic was invented using Regeneron’s VelocImmune ® technology and is a fully human BCMAxCD3 bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on MM cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. Linvoseltamab is administered with an initial step-up dosing regimen followed by the full 200 mg dose administered weekly. At week 14, patients transition to every two-week dosing. A response-adapted regimen further enables patients to shift to every four-week dosing if they achieve and maintain a VGPR or better after having completed at least 24 weeks of therapy. Patients should be hospitalized for 24 hours after administration of the first step-up dose and for 24 hours after administration of the second step-up dose, with the potential for additional hospitalization if patients experience certain adverse events. The generic name for Lynozyfic in its approved U.S. indication is linvoseltamab-gcpt with gcpt as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the FDA. Outside of the U.S., the generic name of Lynozyfic in its approved indications is linvoseltamab. Lynozyfic is also approved in the European Union to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu in due course. About the Linvoseltamab Clinical Development Program The ongoing, open-label, multicenter Phase 1/2 dose-escalation and dose-expansion LINKER-MM1 trial is investigating linvoseltamab in more than 300 enrolled patients with R/R MM. The Phase 1 intravenous dose-escalation portion of the trial – which is now complete – primarily assessed safety, tolerability and dose-limiting toxicities across nine dose levels of linvoseltamab and explored different administration regimens. A subcutaneous Phase 1 portion is ongoing. The Phase 2 intravenous dose expansion portion is ongoing and assessing the safety and anti-tumor activity of linvoseltamab, with the primary endpoint of ORR. Key secondary endpoints include DoR, progression-free survival, rate of minimum residual disease negative status and overall survival. Linvoseltamab is being investigated in a broad clinical development program exploring its use as a monotherapy as well as in combination regimens across different lines of therapy in MM, including earlier lines of treatment, as well as MM precursor and other plasma cell disorders. This includes evaluating linvoseltamab in a Phase 1b trial ( LINKER-MM2 ) in combination with other cancer treatments in R/R MM as well as a Phase 3 confirmatory trial ( LINKER-MM3 ) as a monotherapy in R/R MM. For more information on Regeneron’s clinical trials in blood cancer, visit the clinical trials website , or contact via clinicaltrials@regeneron.com or 1-844-734-6643. About Regeneron in Hematology At Regeneron, we’re applying more than three decades of biology expertise with our proprietary VelociSuite ® technologies to develop medicines for patients with diverse blood cancers and rare blood disorders. Our blood cancer research is focused on bispecific antibodies that are being investigated both as monotherapies and in various combinations and emerging therapeutic modalities. Together, they provide us with unique combinatorial flexibility to develop customized and potentially synergistic cancer treatments. Our research and collaborations to develop potential treatments for rare blood disorders include explorations in antibody medicine, gene editing and gene-knockout technologies, and investigational RNA-approaches focused on depleting abnormal proteins or blocking disease-causing cellular signaling. About Regeneron’s VelocImmune ® Technology Regeneron’s VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron’s co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent ® (dupilumab), Libtayo ® (cemiplimab-rwlc), Praluent ® (alirocumab), Kevzara ® (sarilumab), Evkeeza ® (evinacumab-dgnb), Inmazeb ® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz ® (pozelimab-bbfg). In addition, REGEN-COV ® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. Please see full Prescribing Information , including Boxed WARNING, and Medication Guide for LYNOZYFIC. What is LYNOZYFIC? LYNOZYFIC is a prescription medicine used to treat adults with multiple myeloma who: It is not known if LYNOZYFIC is safe and effective in children. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite ® , which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn , Instagram , Facebook or X . SOURCE: Regeneron Pharmaceuticals